Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
2,115 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A, Réa D, Boquimpani C, et al. · Leukemia · 2023Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
Cortes JE, Saglio G, Kantarjian HM, et al. · J Clin Oncol · 2016Clinical Trial, Phase III, Comparative Study
- Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Cortes J, Apperley J, Lomaia E, et al. · Blood · 2021Clinical Trial, Phase II, Randomized Controlled Trial
- Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
O'Brien SG, Guilhot F, Larson RA, et al. · N Engl J Med · 2003Clinical Trial, Clinical Trial, Phase III
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Hochhaus A, Saglio G, Hughes TP, et al. · Leukemia · 2016Comparative Study, Randomized Controlled Trial
- Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.
Xuan L, Wang Y, Huang F, et al. · Lancet Oncol · 2020Clinical Trial, Phase III, Multicenter Study
- Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
Brümmendorf TH, Cortes JE, Milojkovic D, et al. · Leukemia · 2022Multicenter Study, Randomized Controlled Trial
- Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
Short NJ, Nguyen D, Jabbour E, et al. · Lancet Haematol · 2024Clinical Trial, Phase II
- Systematic review of pre-clinical chronic myeloid leukaemia.
Kuan JW, Su AT, Leong CF, et al. · Int J Hematol · 2018Systematic Review
- Effect of Imatinib Mesylate on Growth in Pediatric Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Gupta P, Banothu KK, Haldar P, et al. · J Pediatr Hematol Oncol · 2023Meta-Analysis, Systematic Review
- Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia.
Huguet F, Réa D, Cayssials E, et al. · Expert Rev Hematol · 2023Clinical Trial, Phase II, Randomized Controlled Trial
- MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis.
Louati N, Turki F, Mnif H, et al. · J Oncol Pharm Pract · 2022Meta-Analysis
- Treatment Outcomes of Intracranial Myeloid Sarcomas: A Meta-Analysis.
Lee D, Omofoye OA, Nuño MA, et al. · World Neurosurg · 2021Meta-Analysis, Systematic Review
- Patient-reported toxicity symptoms during tyrosine kinase inhibitor treatment in chronic myeloid leukemia: a systematic review and meta-analysis.
Smit Y, Scheuter P, Lange MPM, et al. · Support Care Cancer · 2025Systematic Review, Meta-Analysis
- ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.
Zheng Q, Wu H, Yu Q, et al. · Pharmacogenomics J · 2015Meta-Analysis, Research Support, Non-U.S. Gov't
- Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.
Desjonquères A, Chevallier P, Thomas X, et al. · Blood Cancer J · 2016Clinical Trial, Phase II, Clinical Trial, Phase III
- The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis.
Ghalesardi OK, Khosravi A, Azizi E, et al. · Leuk Res · 2021Meta-Analysis, Systematic Review
- Systematic Review of Normal Subjects Harbouring BCR-ABL1 Fusion Gene.
Kuan JW, Su AT, Leong CF, et al. · Acta Haematol · 2020Research Support, Non-U.S. Gov't, Systematic Review
- Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia.
Wu A, Liu X, Fruhstorfer C, et al. · Int J Mol Sci · 2024Systematic Review
- Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.
Xuan L, Wang Y, Yang K, et al. · Lancet Haematol · 2023Randomized Controlled Trial, Multicenter Study
- Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.
Cha SH, Kim K, Song YK · Acta Oncol · 2023Meta-Analysis, Systematic Review
- Single vs double umbilical cord blood transplantation in acute leukemia: Systematic review and meta-analysis.
Odutola PO, Olorunyomi PO, Olorunyomi I · Leuk Res · 2024Meta-Analysis, Systematic Review
- Systematic Review and Meta-Analysis of -New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia.
Pan P, Wang L, Wang Y, et al. · Acta Haematol · 2020Comparative Study, Meta-Analysis
- Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis.
Pasvolsky O, Shimony S, Yeshurun M, et al. · Acta Oncol · 2021Meta-Analysis, Systematic Review
- Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
Padala S, Cortes J · Haematologica · 2023Randomized Controlled Trial
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.